期刊文献+

唑来膦酸治疗原发性骨质疏松症的效果观察 被引量:6

Effects of Zoledronic Acid in Patients with Primary Osteoporosis
原文传递
导出
摘要 目的:研究唑来膦酸在治疗原发性骨质疏松症过程中患者骨密度及疼痛的变化。方法:设计为期两年的随机、前瞻性研究,通过Achilles定量超声(QUS)系统测量骨密度(BMD),进行问卷调查、疼痛评估,共入选60例原发性骨质疏松症患者。随机分为唑来膦酸组和对照组,唑来膦酸组使用唑来膦酸及元素钙治疗;对照组使用元素钙治疗。治疗前后分别进行骨密度测定及疼痛评估,进行对比研究。结果:治疗两年后.与治疗前比较,唑来膦酸组BMD上升(P<0.05);对照组BMD无明显变化(P>0.05)。两组临床获益率分别为73.33%和46.67%,无显著差别(P>0.05)。结论:唑来膦酸治疗原发性骨质疏松症有良好作用,能提高骨密度,对骨质疏松的治疗及预防骨折具有重要的意义。 Objective: To investigate the effects of zoledronic acid on bone mineral density (BMD) and pain during treatment of patients with primary osteoporosis. Methods: This design was a two-year randomized and prospective study. A total of 60 patients were selected and randomly divided into zoledronic acid (ZA) group and control group. ZA group was given zoledronic acid and calcium; control groupl calcium. Bone mineral density (BMD), by Achilles quantitative ultrasound (QUS) systems,was measured and pain was evaluated in the two groups before and after treatment. Results: After two years of treatment, BMD of the patients in ZA group increased (P 〈0.05),compared with before treatment. In control group, BMD had no significant change (P〉0.05) .The rates of clinical benefit of the two groups were 73.33% and 46.67%(P〉0.05 ). Conclusion: Zoledronic acid for patients with primary osteoporosis has beneficial effects, which can improve BMD and plays an important role in the treatment of patients with primary osteoporosis and in the prevention of fractures.
出处 《现代生物医学进展》 CAS 2013年第3期533-535,共3页 Progress in Modern Biomedicine
关键词 唑来膦酸 骨质疏松 强度指数 定量超声 Zoledronic acid Osteoporosis Bone mineral denSity Quantitative ultrasound
  • 相关文献

参考文献17

  • 1应桂英,贾勇,宋彬,栾荣生,邹翎,冯卫,陈治宇,余海涛,郑友成,刘文国,宋志勇,唐书贵.四川崇州市不明原因骨关节病临床表现及X线量化评价[J].中国修复重建外科杂志,2007,21(3):289-294. 被引量:3
  • 2邵敏,刘庆思.绝经后骨质疏松症生存质量的调查研究[J].中国骨质疏松杂志,2000,6(3):58-60. 被引量:17
  • 3Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer [J]. BMJ, 2003,327:469.
  • 4Tauchmanova L, Nuzzo V, Del Puente A, et al. Reduced bone mass detected by bone quantitative uhrasonometry and DEXA in pre-and postmenopansal women with endogenous subclinical hyperthyroidism [J]. Maturitas,2004,48(3):299-306.
  • 5Wear KA. Ultrasonic attenuation in human calcaneus from 0.2 to 1.7 MHz[J]. IEEE Trans Ultrason Ferroelect Freq Contr,2001,48:602-608.
  • 6Njeh CF, Boivin CM, Langton CM. The role of ultrasound in the assessment of osteoporosis:a review[J]. Osteoporosis Int, 1997,7:7-15.
  • 7Tsangari H, Findlay DM, Fazzalari NL, Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood [J]. Bone,2007,40( 1 ):211-217.
  • 8Kurth AA, Kim SZ, Shea M, et al. Preventative ibandronate treatment has the most beneficial effect on the mi crostrueture of bone in experimental tumor osteolysis [J]. J Bone Miner Metab,2007,25 (2): 86-92.
  • 9Limiewski J, Nowicki A, Sawicki A. Detection of bone disease with ultra-sound comparison with bone densitometry[J]. Ultrasonics,2000, 38:693-697.
  • 10徐若男,王丁丁,朱小蔚.预防和治疗骨质疏松症的常用药物[J].东南国防医药,2011,13(6):540-541. 被引量:12

二级参考文献31

共引文献29

同被引文献78

  • 1汪玉海,金丽娟,高俊,沈军,魏松英.脂肪干细胞复合PLGA对骨质疏松骨折愈合后生物力学的影响[J].宁夏医科大学学报,2013,35(3):244-247. 被引量:10
  • 2刘雄.阿伦膦酸钠治疗原发性骨质疏松症的4年临床研究[J].现代生物医学进展,2009,9(24):4722-4724. 被引量:7
  • 3卢化爱.绝经后骨质疏松发病率调查与预防[J].中国妇幼保健,2007,22(21):3033-3034. 被引量:11
  • 4陶国权,刘忠厚.老年性骨质疏松[M].北京:北京科技出版社.1998:535-543.
  • 5中华人民共和国卫生部医政司.中国康复医学诊疗规范[M].北京:华夏出版社,1999.129.
  • 6Kanis J A,Melton L J,Christiansenc C,et al.Thediagnosis of osteoporosis [J].J Bone Miner Res,1994,9(8): 1137-1141.
  • 7King A E,Umland E M.Osteonecrosis of the jaw inpatients receiving intravenous or oral bisphosphonates [J].Pharmacotherapy,2008,28(5): 667-677.
  • 8Recker R R,Delmas P D,Halse J,et a1.Effects ofintravenous zoledronic acid once yearly on boneremodeling and bone structure [J].Bone Miner Res,2008,23(1): 6-16.
  • 9Hirsh V,Tchekmedyian N S,Rosen L S,et a1.Clinicalbenefit of zoledronic acid in patients with lung cancer andother solid tumors:analysis based on history of skeletalcomplications [J].Clin Lung Cancer,2004,6(3): 170-174.
  • 10Oiel I J,Bergner R,Hirschberg R.Safety and convenienceof a 15-minute infusion of zoledronic acid [J].Oncologist,2005,10(1): 82-83.

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部